Skip to main content
. 2020 Jul 7;75(10):3082–3084. doi: 10.1093/jac/dkaa234

Figure 1.

Figure 1

(a) Median (IQR) plasma concentrations for dolutegravir (DTG) and darunavir (DRV) after Week 4, 12 and 24 in a subset of 57 subjects within substudy PK II of the DUALIS study. Distribution of plasma levels of (b) dolutegravir and (c) darunavir in hours after last reported intake at Week 4, 12 and 24. Each cross represents one subject.